Table of Content

1 Report Overview
1.1 Sickle Cell Disease Drug Definition
1.2 Market by Type
1.2.1 Global Sickle Cell Disease Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 ARQ-092
1.2.3 BIVV-003
1.2.4 CAL-H
1.2.5 CTX-001
1.2.6 DRX-194
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Sickle Cell Disease Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Sickle Cell Disease Drug Sales
2.1 Global Sickle Cell Disease Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Sickle Cell Disease Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Sickle Cell Disease Drug Revenue by Region
2.3.1 Global Sickle Cell Disease Drug Revenue by Region (2018-2023)
2.3.2 Global Sickle Cell Disease Drug Revenue by Region (2024-2034)
2.4 Global Sickle Cell Disease Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Sickle Cell Disease Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Sickle Cell Disease Drug Sales Quantity by Region
2.6.1 Global Sickle Cell Disease Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Sickle Cell Disease Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Sickle Cell Disease Drug Sales Quantity by Manufacturers
3.1.1 Global Sickle Cell Disease Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Sickle Cell Disease Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Sickle Cell Disease Drug Sales in 2024
3.2 Global Sickle Cell Disease Drug Revenue by Manufacturers
3.2.1 Global Sickle Cell Disease Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Sickle Cell Disease Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Sickle Cell Disease Drug Revenue in 2024
3.3 Global Sickle Cell Disease Drug Sales Price by Manufacturers
3.4 Global Key Players of Sickle Cell Disease Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Sickle Cell Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Sickle Cell Disease Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Sickle Cell Disease Drug, Product Offered and Application
3.8 Global Key Manufacturers of Sickle Cell Disease Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Sickle Cell Disease Drug Sales Quantity by Type
4.1.1 Global Sickle Cell Disease Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Sickle Cell Disease Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Sickle Cell Disease Drug Revenue by Type
4.2.1 Global Sickle Cell Disease Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Sickle Cell Disease Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
4.3 Global Sickle Cell Disease Drug Price by Type
4.3.1 Global Sickle Cell Disease Drug Price by Type (2018-2023)
4.3.2 Global Sickle Cell Disease Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Sickle Cell Disease Drug Sales Quantity by Application
5.1.1 Global Sickle Cell Disease Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Sickle Cell Disease Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Sickle Cell Disease Drug Revenue by Application
5.2.1 Global Sickle Cell Disease Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Sickle Cell Disease Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
5.3 Global Sickle Cell Disease Drug Price by Application
5.3.1 Global Sickle Cell Disease Drug Price by Application (2018-2023)
5.3.2 Global Sickle Cell Disease Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Sickle Cell Disease Drug Sales by Company
6.1.1 North America Sickle Cell Disease Drug Revenue by Company (2018-2023)
6.1.2 North America Sickle Cell Disease Drug Sales Quantity by Company (2018-2023)
6.2 North America Sickle Cell Disease Drug Market Size by Type
6.2.1 North America Sickle Cell Disease Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Sickle Cell Disease Drug Revenue by Type (2018-2034)
6.3 North America Sickle Cell Disease Drug Market Size by Application
6.3.1 North America Sickle Cell Disease Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Sickle Cell Disease Drug Revenue by Application (2018-2034)
6.4 North America Sickle Cell Disease Drug Market Size by Country
6.4.1 North America Sickle Cell Disease Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Sickle Cell Disease Drug Revenue by Country (2018-2034)
6.4.3 North America Sickle Cell Disease Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Sickle Cell Disease Drug Sales by Company
7.1.1 Europe Sickle Cell Disease Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Sickle Cell Disease Drug Revenue by Company (2018-2023)
7.2 Europe Sickle Cell Disease Drug Market Size by Type
7.2.1 Europe Sickle Cell Disease Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Sickle Cell Disease Drug Revenue by Type (2018-2034)
7.3 Europe Sickle Cell Disease Drug Market Size by Application
7.3.1 Europe Sickle Cell Disease Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Sickle Cell Disease Drug Revenue by Application (2018-2034)
7.4 Europe Sickle Cell Disease Drug Market Size by Country
7.4.1 Europe Sickle Cell Disease Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Sickle Cell Disease Drug Revenue by Country (2018-2034)
7.4.3 Europe Sickle Cell Disease Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Sickle Cell Disease Drug Sales by Company
8.1.1 China Sickle Cell Disease Drug Sales Quantity by Company (2018-2023)
8.1.2 China Sickle Cell Disease Drug Revenue by Company (2018-2023)
8.2 China Sickle Cell Disease Drug Market Size by Type
8.2.1 China Sickle Cell Disease Drug Sales Quantity by Type (2018-2034)
8.2.2 China Sickle Cell Disease Drug Revenue by Type (2018-2034)
8.3 China Sickle Cell Disease Drug Market Size by Application
8.3.1 China Sickle Cell Disease Drug Sales Quantity by Application (2018-2034)
8.3.2 China Sickle Cell Disease Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Sickle Cell Disease Drug Sales by Company
9.1.1 APAC Sickle Cell Disease Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Sickle Cell Disease Drug Revenue by Company (2018-2023)
9.2 APAC Sickle Cell Disease Drug Market Size by Type
9.2.1 APAC Sickle Cell Disease Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Sickle Cell Disease Drug Revenue by Type (2018-2034)
9.3 APAC Sickle Cell Disease Drug Market Size by Application
9.3.1 APAC Sickle Cell Disease Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Sickle Cell Disease Drug Revenue by Application (2018-2034)
9.4 APAC Sickle Cell Disease Drug Market Size by Region
9.4.1 APAC Sickle Cell Disease Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Sickle Cell Disease Drug Revenue by Region (2018-2034)
9.4.3 APAC Sickle Cell Disease Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Sickle Cell Disease Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Sickle Cell Disease Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Sickle Cell Disease Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Sickle Cell Disease Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Acceleron Pharma Inc
11.1.1 Acceleron Pharma Inc Company Information
11.1.2 Acceleron Pharma Inc Overview
11.1.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Acceleron Pharma Inc Sickle Cell Disease Drug Products and Services
11.1.5 Acceleron Pharma Inc Sickle Cell Disease Drug SWOT Analysis
11.1.6 Acceleron Pharma Inc Recent Developments
11.2 Addmedica SAS
11.2.1 Addmedica SAS Company Information
11.2.2 Addmedica SAS Overview
11.2.3 Addmedica SAS Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Addmedica SAS Sickle Cell Disease Drug Products and Services
11.2.5 Addmedica SAS Sickle Cell Disease Drug SWOT Analysis
11.2.6 Addmedica SAS Recent Developments
11.3 Angiocrine Bioscience Inc
11.3.1 Angiocrine Bioscience Inc Company Information
11.3.2 Angiocrine Bioscience Inc Overview
11.3.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Products and Services
11.3.5 Angiocrine Bioscience Inc Sickle Cell Disease Drug SWOT Analysis
11.3.6 Angiocrine Bioscience Inc Recent Developments
11.4 Annexin Pharmaceuticals AB
11.4.1 Annexin Pharmaceuticals AB Company Information
11.4.2 Annexin Pharmaceuticals AB Overview
11.4.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Products and Services
11.4.5 Annexin Pharmaceuticals AB Sickle Cell Disease Drug SWOT Analysis
11.4.6 Annexin Pharmaceuticals AB Recent Developments
11.5 ArQule Inc
11.5.1 ArQule Inc Company Information
11.5.2 ArQule Inc Overview
11.5.3 ArQule Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 ArQule Inc Sickle Cell Disease Drug Products and Services
11.5.5 ArQule Inc Sickle Cell Disease Drug SWOT Analysis
11.5.6 ArQule Inc Recent Developments
11.6 Bio Products Laboratory Ltd
11.6.1 Bio Products Laboratory Ltd Company Information
11.6.2 Bio Products Laboratory Ltd Overview
11.6.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Products and Services
11.6.5 Bio Products Laboratory Ltd Sickle Cell Disease Drug SWOT Analysis
11.6.6 Bio Products Laboratory Ltd Recent Developments
11.7 Bioverativ Inc
11.7.1 Bioverativ Inc Company Information
11.7.2 Bioverativ Inc Overview
11.7.3 Bioverativ Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Bioverativ Inc Sickle Cell Disease Drug Products and Services
11.7.5 Bioverativ Inc Sickle Cell Disease Drug SWOT Analysis
11.7.6 Bioverativ Inc Recent Developments
11.8 bluebird bio Inc
11.8.1 bluebird bio Inc Company Information
11.8.2 bluebird bio Inc Overview
11.8.3 bluebird bio Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 bluebird bio Inc Sickle Cell Disease Drug Products and Services
11.8.5 bluebird bio Inc Sickle Cell Disease Drug SWOT Analysis
11.8.6 bluebird bio Inc Recent Developments
11.9 Bristol-Myers Squibb Co
11.9.1 Bristol-Myers Squibb Co Company Information
11.9.2 Bristol-Myers Squibb Co Overview
11.9.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Products and Services
11.9.5 Bristol-Myers Squibb Co Sickle Cell Disease Drug SWOT Analysis
11.9.6 Bristol-Myers Squibb Co Recent Developments
11.10 Calimmune Inc
11.10.1 Calimmune Inc Company Information
11.10.2 Calimmune Inc Overview
11.10.3 Calimmune Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Calimmune Inc Sickle Cell Disease Drug Products and Services
11.10.5 Calimmune Inc Sickle Cell Disease Drug SWOT Analysis
11.10.6 Calimmune Inc Recent Developments
11.11 CRISPR Therapeutics
11.11.1 CRISPR Therapeutics Company Information
11.11.2 CRISPR Therapeutics Overview
11.11.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 CRISPR Therapeutics Sickle Cell Disease Drug Products and Services
11.11.5 CRISPR Therapeutics Recent Developments
11.12 CSL Ltd
11.12.1 CSL Ltd Company Information
11.12.2 CSL Ltd Overview
11.12.3 CSL Ltd Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 CSL Ltd Sickle Cell Disease Drug Products and Services
11.12.5 CSL Ltd Recent Developments
11.13 Daiichi Sankyo Co Ltd
11.13.1 Daiichi Sankyo Co Ltd Company Information
11.13.2 Daiichi Sankyo Co Ltd Overview
11.13.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Products and Services
11.13.5 Daiichi Sankyo Co Ltd Recent Developments
11.14 Editas Medicine Inc
11.14.1 Editas Medicine Inc Company Information
11.14.2 Editas Medicine Inc Overview
11.14.3 Editas Medicine Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Editas Medicine Inc Sickle Cell Disease Drug Products and Services
11.14.5 Editas Medicine Inc Recent Developments
11.15 Errant Gene Therapeutics LLC
11.15.1 Errant Gene Therapeutics LLC Company Information
11.15.2 Errant Gene Therapeutics LLC Overview
11.15.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Products and Services
11.15.5 Errant Gene Therapeutics LLC Recent Developments
11.16 Gamida Cell Ltd
11.16.1 Gamida Cell Ltd Company Information
11.16.2 Gamida Cell Ltd Overview
11.16.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 Gamida Cell Ltd Sickle Cell Disease Drug Products and Services
11.16.5 Gamida Cell Ltd Recent Developments
11.17 Genethon SA
11.17.1 Genethon SA Company Information
11.17.2 Genethon SA Overview
11.17.3 Genethon SA Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Genethon SA Sickle Cell Disease Drug Products and Services
11.17.5 Genethon SA Recent Developments
11.18 Gilead Sciences Inc
11.18.1 Gilead Sciences Inc Company Information
11.18.2 Gilead Sciences Inc Overview
11.18.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Gilead Sciences Inc Sickle Cell Disease Drug Products and Services
11.18.5 Gilead Sciences Inc Recent Developments
11.19 Global Blood Therapeutics Inc
11.19.1 Global Blood Therapeutics Inc Company Information
11.19.2 Global Blood Therapeutics Inc Overview
11.19.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 Global Blood Therapeutics Inc Sickle Cell Disease Drug Products and Services
11.19.5 Global Blood Therapeutics Inc Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Sickle Cell Disease Drug Value Chain Analysis
12.2 Sickle Cell Disease Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Sickle Cell Disease Drug Production Mode & Process
12.4 Sickle Cell Disease Drug Sales and Marketing
12.4.1 Sickle Cell Disease Drug Sales Channels
12.4.2 Sickle Cell Disease Drug Distributors
12.5 Sickle Cell Disease Drug Customers
13 Market Dynamics
13.1 Sickle Cell Disease Drug Industry Trends
13.2 Sickle Cell Disease Drug Market Drivers
13.3 Sickle Cell Disease Drug Market Challenges
13.4 Sickle Cell Disease Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of ARQ-092
Table 3. Major Manufacturers of BIVV-003
Table 4. Major Manufacturers of CAL-H
Table 5. Major Manufacturers of CTX-001
Table 6. Major Manufacturers of DRX-194
Table 7. Major Manufacturers of Others
Table 8. Global Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Sickle Cell Disease Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Sickle Cell Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Sickle Cell Disease Drug Revenue Market Share by Region (2018-2023)
Table 12. Global Sickle Cell Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Sickle Cell Disease Drug Revenue Market Share by Region (2024-2034)
Table 14. Global Sickle Cell Disease Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 15. Global Sickle Cell Disease Drug Sales by Region (2018-2023) & (K Pcs)
Table 16. Global Sickle Cell Disease Drug Sales Market Share by Region (2018-2023)
Table 17. Global Sickle Cell Disease Drug Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Sickle Cell Disease Drug Sales Market Share by Region (2024-2034)
Table 19. Global Sickle Cell Disease Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 20. Global Sickle Cell Disease Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 21. Global Sickle Cell Disease Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 22. Global Sickle Cell Disease Drug Revenue Share by Manufacturers (2018-2023)
Table 23. Global Sickle Cell Disease Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 24. Global Key Players of Sickle Cell Disease Drug, Industry Ranking, 2021 VS 2024
Table 25. Global Sickle Cell Disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Sickle Cell Disease Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Sickle Cell Disease Drug as of 2024)
Table 27. Global Key Manufacturers of Sickle Cell Disease Drug, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Sickle Cell Disease Drug, Product Offered and Application
Table 29. Global Key Manufacturers of Sickle Cell Disease Drug, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Sickle Cell Disease Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 32. Global Sickle Cell Disease Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Sickle Cell Disease Drug Sales Quantity Share by Type (2018-2023)
Table 34. Global Sickle Cell Disease Drug Sales Quantity Share by Type (2024-2034)
Table 35. Global Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 36. Global Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Sickle Cell Disease Drug Revenue Share by Type (2018-2023)
Table 38. Global Sickle Cell Disease Drug Revenue Share by Type (2024-2034)
Table 39. Sickle Cell Disease Drug Price by Type (2018-2023) & (USD/Pcs)
Table 40. Global Sickle Cell Disease Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Sickle Cell Disease Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 42. Global Sickle Cell Disease Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Sickle Cell Disease Drug Sales Quantity Share by Application (2018-2023)
Table 44. Global Sickle Cell Disease Drug Sales Quantity Share by Application (2024-2034)
Table 45. Global Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 46. Global Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Sickle Cell Disease Drug Revenue Share by Application (2018-2023)
Table 48. Global Sickle Cell Disease Drug Revenue Share by Application (2024-2034)
Table 49. Sickle Cell Disease Drug Price by Application (2018-2023) & (USD/Pcs)
Table 50. Global Sickle Cell Disease Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Sickle Cell Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 52. North America Sickle Cell Disease Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 53. North America Sickle Cell Disease Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 54. North America Sickle Cell Disease Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 56. North America Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Sickle Cell Disease Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 58. North America Sickle Cell Disease Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 60. North America Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Sickle Cell Disease Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 62. North America Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 63. North America Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Sickle Cell Disease Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 65. North America Sickle Cell Disease Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Sickle Cell Disease Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 67. Europe Sickle Cell Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 68. Europe Sickle Cell Disease Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 69. Europe Sickle Cell Disease Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 71. Europe Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Sickle Cell Disease Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 73. Europe Sickle Cell Disease Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 75. Europe Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Sickle Cell Disease Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 77. Europe Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 78. Europe Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Sickle Cell Disease Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 80. Europe Sickle Cell Disease Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Sickle Cell Disease Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 82. China Sickle Cell Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 83. China Sickle Cell Disease Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 84. China Sickle Cell Disease Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 86. China Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Sickle Cell Disease Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 88. China Sickle Cell Disease Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 90. China Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Sickle Cell Disease Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 92. APAC Sickle Cell Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 93. APAC Sickle Cell Disease Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 94. APAC Sickle Cell Disease Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 96. APAC Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Sickle Cell Disease Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 98. APAC Sickle Cell Disease Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 100. APAC Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Sickle Cell Disease Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 102. APAC Sickle Cell Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 103. APAC Sickle Cell Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Sickle Cell Disease Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 105. APAC Sickle Cell Disease Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Company (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 109. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 113. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 118. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 120. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. Acceleron Pharma Inc Company Information
Table 122. Acceleron Pharma Inc Description and Overview
Table 123. Acceleron Pharma Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 124. Acceleron Pharma Inc Sickle Cell Disease Drug Product and Services
Table 125. Acceleron Pharma Inc Sickle Cell Disease Drug SWOT Analysis
Table 126. Acceleron Pharma Inc Recent Developments
Table 127. Addmedica SAS Company Information
Table 128. Addmedica SAS Description and Overview
Table 129. Addmedica SAS Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 130. Addmedica SAS Sickle Cell Disease Drug Product and Services
Table 131. Addmedica SAS Sickle Cell Disease Drug SWOT Analysis
Table 132. Addmedica SAS Recent Developments
Table 133. Angiocrine Bioscience Inc Company Information
Table 134. Angiocrine Bioscience Inc Description and Overview
Table 135. Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 136. Angiocrine Bioscience Inc Sickle Cell Disease Drug Product and Services
Table 137. Angiocrine Bioscience Inc Sickle Cell Disease Drug SWOT Analysis
Table 138. Angiocrine Bioscience Inc Recent Developments
Table 139. Annexin Pharmaceuticals AB Company Information
Table 140. Annexin Pharmaceuticals AB Description and Overview
Table 141. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 142. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product and Services
Table 143. Annexin Pharmaceuticals AB Sickle Cell Disease Drug SWOT Analysis
Table 144. Annexin Pharmaceuticals AB Recent Developments
Table 145. ArQule Inc Company Information
Table 146. ArQule Inc Description and Overview
Table 147. ArQule Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 148. ArQule Inc Sickle Cell Disease Drug Product and Services
Table 149. ArQule Inc Sickle Cell Disease Drug SWOT Analysis
Table 150. ArQule Inc Recent Developments
Table 151. Bio Products Laboratory Ltd Company Information
Table 152. Bio Products Laboratory Ltd Description and Overview
Table 153. Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 154. Bio Products Laboratory Ltd Sickle Cell Disease Drug Product and Services
Table 155. Bio Products Laboratory Ltd Sickle Cell Disease Drug SWOT Analysis
Table 156. Bio Products Laboratory Ltd Recent Developments
Table 157. Bioverativ Inc Company Information
Table 158. Bioverativ Inc Description and Overview
Table 159. Bioverativ Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 160. Bioverativ Inc Sickle Cell Disease Drug Product and Services
Table 161. Bioverativ Inc Sickle Cell Disease Drug SWOT Analysis
Table 162. Bioverativ Inc Recent Developments
Table 163. bluebird bio Inc Company Information
Table 164. bluebird bio Inc Description and Overview
Table 165. bluebird bio Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 166. bluebird bio Inc Sickle Cell Disease Drug Product and Services
Table 167. bluebird bio Inc Sickle Cell Disease Drug SWOT Analysis
Table 168. bluebird bio Inc Recent Developments
Table 169. Bristol-Myers Squibb Co Company Information
Table 170. Bristol-Myers Squibb Co Description and Overview
Table 171. Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 172. Bristol-Myers Squibb Co Sickle Cell Disease Drug Product and Services
Table 173. Bristol-Myers Squibb Co Sickle Cell Disease Drug SWOT Analysis
Table 174. Bristol-Myers Squibb Co Recent Developments
Table 175. Calimmune Inc Company Information
Table 176. Calimmune Inc Description and Overview
Table 177. Calimmune Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 178. Calimmune Inc Sickle Cell Disease Drug Product and Services
Table 179. Calimmune Inc Sickle Cell Disease Drug SWOT Analysis
Table 180. Calimmune Inc Recent Developments
Table 181. CRISPR Therapeutics Company Information
Table 182. CRISPR Therapeutics Description and Overview
Table 183. CRISPR Therapeutics Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 184. CRISPR Therapeutics Sickle Cell Disease Drug Product and Services
Table 185. CRISPR Therapeutics Recent Developments
Table 186. CSL Ltd Company Information
Table 187. CSL Ltd Description and Overview
Table 188. CSL Ltd Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 189. CSL Ltd Sickle Cell Disease Drug Product and Services
Table 190. CSL Ltd Recent Developments
Table 191. Daiichi Sankyo Co Ltd Company Information
Table 192. Daiichi Sankyo Co Ltd Description and Overview
Table 193. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 194. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product and Services
Table 195. Daiichi Sankyo Co Ltd Recent Developments
Table 196. Editas Medicine Inc Company Information
Table 197. Editas Medicine Inc Description and Overview
Table 198. Editas Medicine Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 199. Editas Medicine Inc Sickle Cell Disease Drug Product and Services
Table 200. Editas Medicine Inc Recent Developments
Table 201. Errant Gene Therapeutics LLC Company Information
Table 202. Errant Gene Therapeutics LLC Description and Overview
Table 203. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 204. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product and Services
Table 205. Errant Gene Therapeutics LLC Recent Developments
Table 206. Gamida Cell Ltd Company Information
Table 207. Gamida Cell Ltd Description and Overview
Table 208. Gamida Cell Ltd Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 209. Gamida Cell Ltd Sickle Cell Disease Drug Product and Services
Table 210. Gamida Cell Ltd Recent Developments
Table 211. Genethon SA Company Information
Table 212. Genethon SA Description and Overview
Table 213. Genethon SA Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 214. Genethon SA Sickle Cell Disease Drug Product and Services
Table 215. Genethon SA Recent Developments
Table 216. Gilead Sciences Inc Company Information
Table 217. Gilead Sciences Inc Description and Overview
Table 218. Gilead Sciences Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 219. Gilead Sciences Inc Sickle Cell Disease Drug Product and Services
Table 220. Gilead Sciences Inc Recent Developments
Table 221. Global Blood Therapeutics Inc Company Information
Table 222. Global Blood Therapeutics Inc Description and Overview
Table 223. Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 224. Global Blood Therapeutics Inc Sickle Cell Disease Drug Product and Services
Table 225. Global Blood Therapeutics Inc Recent Developments
Table 226. Key Raw Materials Lists
Table 227. Raw Materials Key Suppliers Lists
Table 228. Sickle Cell Disease Drug Distributors List
Table 229. Sickle Cell Disease Drug Customers List
Table 230. Sickle Cell Disease Drug Market Trends
Table 231. Sickle Cell Disease Drug Market Drivers
Table 232. Sickle Cell Disease Drug Market Challenges
Table 233. Sickle Cell Disease Drug Market Restraints
Table 234. Research Programs/Design for This Report
Table 235. Key Data Information from Secondary Sources
Table 236. Key Data Information from Primary Sources
List of Figures
Figure 1. Sickle Cell Disease Drug Product Picture
Figure 2. Global Sickle Cell Disease Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Sickle Cell Disease Drug Market Share by Type in 2024 & 2034
Figure 4. ARQ-092 Product Picture
Figure 5. BIVV-003 Product Picture
Figure 6. CAL-H Product Picture
Figure 7. CTX-001 Product Picture
Figure 8. DRX-194 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Sickle Cell Disease Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 11. Global Sickle Cell Disease Drug Market Share by Application in 2024 & 2034
Figure 12. Hospital
Figure 13. Clinic
Figure 14. Others
Figure 15. Sickle Cell Disease Drug Report Years Considered
Figure 16. Global Sickle Cell Disease Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Sickle Cell Disease Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Sickle Cell Disease Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Sickle Cell Disease Drug Sales Quantity 2018-2034 (K Pcs)
Figure 20. Global Sickle Cell Disease Drug Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Sickle Cell Disease Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Sickle Cell Disease Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. North America Sickle Cell Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Sickle Cell Disease Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. Europe Sickle Cell Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Sickle Cell Disease Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. China Sickle Cell Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Sickle Cell Disease Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. APAC Sickle Cell Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Sickle Cell Disease Drug Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Sickle Cell Disease Drug Revenue in 2024
Figure 34. Sickle Cell Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 35. Global Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 37. Global Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 39. North America Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 40. North America Sickle Cell Disease Drug Sales Quantity Market Share by Company in 2024
Figure 41. North America Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 43. North America Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 45. North America Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 46. North America Sickle Cell Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Sickle Cell Disease Drug Sales Quantity Market Share by Company in 2024
Figure 50. Europe Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 51. Europe Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 53. Europe Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 55. Europe Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 56. Europe Sickle Cell Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 58. France Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 62. China Sickle Cell Disease Drug Sales Quantity Market Share by Company in 2024
Figure 63. China Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 64. China Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 66. China Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 68. APAC Sickle Cell Disease Drug Sales Quantity Market Share by Company in 2024
Figure 69. APAC Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 70. APAC Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 72. APAC Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 74. APAC Sickle Cell Disease Drug Revenue Share by Region (2018-2034)
Figure 75. APAC Sickle Cell Disease Drug Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 80. India Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Sickle Cell Disease Drug Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 89. Brazil Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 94. Sickle Cell Disease Drug Value Chain
Figure 95. Sickle Cell Disease Drug Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed